Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

N.J. DRUG EXECS PITCH VOLUNTARY PRICE CONTROLS TO COMMERCE SECTY. Ron Brown at a private March 24 meeting arranged by New Jersey Democratic Governor James Florio. Reinforcing the plan announced by the Pharmaceutical Manufacturers Association in mid- March to hold price increases to the CPI, the heads of 13 major pharmaceutical companies with headquarters in New Jersey met with Brown to deliver their message of voluntary price controls. Brown is said to have demonstrated a "willingness" to convey the pharmaceutical industry's concerns about price controls to President Clinton. Pharmaceutical execs at the Commerce lobbying meeting included: Hoffmann-La Roche Chairman Irwin Lerner; American Home Products Chairman John Stafford; Bristol-Myers Squibb Exec VP Kenneth Weg; Johnson & Johnson CEO Ralph Larsen; Lederle Group VP David Bethune; Merck Exec VP John Zabriskie; Pfizer CEO William Steere; Reed & Carnrick President John Spitznagel; Sandoz CEO Tim Rothwell; Sandoz VP Denis Grady; Schering-Plough Exec-VP Hugh D'Andrade; Parke-Davis President Harold Oberkfell; and Hoechst-Celanese Exec-VP Joseph Patterson. Although mostly focused on price controls, the meeting with Brown also touched on health care reform and other issues relevant to the pharmaceutical industry. Several of the pharmaceutical company execs also met in a same-day closed session with 16 members of New Jersey's congressional delegation on Capitol Hill. The New Jersey delegation meetings continue the effort by drug industry execs to find a receptive audience in the new administration for their message about pharmaceuticals.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts